Diagnostic Values of Clusterin and α-Klotho Levels in Patients with Sarcoidosis

Sarkoidozlu Hastalarda Clusterin ve α-Klotho Düzeylerinin Tanısal Değerleri

Öz

Amaç: Sarkoidoz, etiyolojisi bilinmeyen ve non-kasei̇fi̇ye granülomatöz inflamasyon ile karakterize multifaktörü̇l bir hastalı̇ktır. Sarkoidoz patogenezi ise inflamasyon ve otoimmün aktivasyon olarak tanımlanır. Bu nedenle sarkoidoz hastalığından plazma clusterin ve α-klotho düzeyleriğini değerlendirmeyi amaçladık.

Hastalar ve Yöntem: Sarkoidozlu 40 hasta (ortalama yaş: 52.10±12.60 yıl; 12 erkek, 28 kadın) ve 40 sağlıklı gönüllü (ortalama yaş: 37.40±18.20 yıl; 12 erkek, 28 kadın) Kasım 2019-Mart 2020 tarihleri arasında çalışmaya alındı. Her iki gruptan alınan kan örnekleri ile plazma clusterin ve α-klotho düzeyleri enzime bağlı immunsorban testi (ELISA) ile araştırıldı.

Bulgular: Sarkoidozlu hastalarda plazma clusterin düzeyleri (309.73±40.68 ng/ml) sağlıklı gruba (117.86±102.03 ng/ml) kıyasla anlamlı olarak daha yüksekti (p=0.005). α-klotho plazma düzeyleri ise sarkoidoz grubunda 5.34±7.30 ng/ml ve sağlıklı grupta 7.21±9.84 ng/mL olarak belirlendi, minimal bir azalma gözlemendi ancak istatistiksel olarak anlamılı bir fark yoktu (p=0.338). Sarkoidoz hastaların hemoglobin düzeylerinin sarkoidozunun bağımsız etkilediği bir bulguya işaret etmektedir (12.93±1.02 g/dL ve 14.06±1.50 g/dL) (p=0.012).

Sonuç: Sarcoidozun bağımsız olarak yüksek seviyelerde clusterin ile ilişkili olduğu sonucuna varılı̇z. Plazma clusterin düzeyleri sindiricilikleri için potansiyel bir biyobelirteç olarak kabul edilebilir. Literatürde bu çalışma, sarkoidozda clusterin ve α-klotho'nun plazma seviyeleri için bilgi verilen ilk çalışmalarıdır. Hemoglobin düzeylerinin sarkoidozunun bağımsız bir faktör olduğu sonucuna varılı̇z. Bu konuda daha fazla ve kapsamlı araştırmalarla ilham gövdesi oluşabilir.

Anahtar Kelimeler: Sarkoidoz, clusterin, α-klotho, inflammation, akciğer hastalığı

Abstract

Aim: Sarcoidosis is a multifactorial disease with unknown aetiology and characterized by non-caseous granulomatous inflammation. The pathogenesis of sarcoidosis is defined as inflammation and autoimmune activation. Here, we aimed to evaluate plasma clusterin (CLU) and α-klotho levels in patients with sarcoidosis.

Patients and Methods: Forty patients with sarcoidosis (mean age: 52.10±12.60 years; 12 males, 28 females) and 40 healthy volunteers (mean age: 37.40±18.20 years; 12 males, 28 females) between November 2019-March 2020 were enrolled into the study. Blood samples were drawn from both groups, and plasma CLU and α-klotho levels were investigated by enzyme-linked immunosorbent assay (ELISA) technique.

Results: Patients with sarcoidosis had significantly higher plasma levels of CLU (309.73±40.68 mg/L), compared with healthy controls (117.86±102.03 mg/L) (p=0.005). The plasma levels of α-klotho were measured as 5.34±7.30 mg/L in the sarcoidosis patients and 7.21±9.84 mg/L in the controls. A minimal decrease was observed, but there was no statistically significant difference (p=0.338). The hemoglobin levels of sarcoidosis patients were decreased, when compared with the control group (12.93±1.02 g/dL vs 14.06±1.50 g/dL) (p=0.012).

Conclusion: We concluded that sarcoidosis is associated with high levels of CLU. Plasma CLU may be a potential biomarker of sarcoidosis. Based on literature and to the best of our knowledge, this is the first study to provide insight in the determination of plasma levels of CLU and α-klotho in sarcoidosis. Further and comprehensive investigations are needed to clarify the entity.

Key words: Sarcoidosis, clusterin, α-klotho, inflammation, pulmonary disease

Cite this article as: Akdag T, Korkmaz C. Diagnostic Values of Clusterin and α-Klotho Levels in Patients with Sarcoidosis. Selcuk Med J 2021;37(1): 39-44

Disclosure: None of the authors has a financial interest in any of the products, devices, or drugs mentioned in this article. The research was not sponsored by an outside organization. All authors have agreed to allow full access to the primary data and to allow the journal to review the data if requested.
INTRODUCTION

Sarcoidosis is a multifactorial disease with unknown aetiology and characterized by non-caseous granulomatous inflammation. While affecting all races and both genders, sarcoidosis is usually encountered in young and middle-aged adults (1). Although the most affected areas are mediastinal lymph nodes and lungs, the involvements may be seen in many organs, such as the heart, liver, peripheral lymph nodes, salivary glands, nervous system, musculoskeletal system, hilar lymphadenopathy, eyes and skin (2). The diagnosis of sarcoidosis is performed under the following criteria: a) clinical, laboratory and radiographic findings b) the combination of the histopathological findings that can be displayed in more than one system with the non-caseating epitelioid cell granuloma, c) the exclusion of other causes leading to granulomatous inflammation, and d) the histological analysis of the tissue for the identification of non-caseating granulomas (3).

Although the etiology of sarcoidosis has yet to be elucidated, some factors have recently been proposed, such as oxidative stress, genetic susceptibility, environmental exposure, infections, putative antigens and autoimmune activation (4). An unknown antigen processed by activated macrophages induces an immune response regulated by macrophages and T-cells. These activated cells release different mediators, including cytokines, reactive oxygen species and chemokines, by acting a role in the pathogenesis of sarcoidosis (5). In practice, novel biomarkers have been suggested for the diagnosis of sarcoidosis, but none has been accepted completely yet.

Clusterin (CLU), known previously as apolipoprotein J/ApoJ, is a heterodimeric protein (disulfide-linked) with 75-80 kDa and highly conserved in mammalian tissues (6). The gene of CLU is located on the chromosome 8p21.1 and encodes CLU glycoprotein expressed in nearly all tissues, including brain, testes, liver, pancreas, heart, kidney and lungs (7,8). As a member of the small heat shock protein family, CLU is also a stress-induced molecular chaperone (9). CLU is involved in many physiological processes, such as oxidative stress, lipid transport and membrane remodeling (10). The expressions of CLU are elevated in acute myocardial infarction, inflammation, myocarditis and atherosclerosis (11). Also, CLU has been linked to oxidative stress in both chronic obstructive pulmonary disease (COPD) and asthma (12).

As a transmembrane protein, α-klotho, composed of two parts as the elongation from outside the cell into cytoplasm and upon the membrane surface, consists of 1014 amino acids and weighs about 130 kD. Besides, α-klotho forms the complexes by fibroblast growth factor receptors (FGFR) and serves as a coreceptor for FGFR-23 (13). The gene of α-klotho localized at the 13q12 chromosomal region in humans and composed of five exons and four introns (14). In physiological processes, α-klotho plays a role in maintaining the homeostasis of calcium and phosphate, buffering of elevated reactive oxygen species and the modulation of cell proliferation (15). In addition, α-klotho can suppress oxidative stress and inflammation, so it may reduce oxidative damage in pulmonary epithelia (16).

The aim of the present study was to determine the plasma CLU and α-klotho levels, and to assess the potential role of these biomarkers in the patients with sarcoidosis. In the light of literature and to our knowledge, the plasma levels of CLU and α-klotho have yet to be investigated previously in sarcoidosis patients.

PATIENTS AND METHODS

Eighty participants were enrolled into this cross-sectional study and divided into two groups as the patients and healthy volunteers. The patients’ group was constituted from sarcoidosis patients (28 women and 12 men) admitted to the department of pulmonary disease in between November 2019 and March 2020. The control group composed of the healthy volunteers (28 women and 12 men) was selected among the participants with no complaints related to sarcoidosis. The participants between the ages of 18-65 were enrolled into the study. None of the participants were detected to have a metabolic disease before the study. Those with the following criteria were excluded out of the study: Known endocrinopathies, neoplastic disorders, cardiovascular diseases, thyroid disease, pregnancy, diabetes mellitus and hypertension for at least 3 months. The sarcoidosis patients were diagnosed by an experienced clinician, and the cases were also confirmed by lung X-rays and high resolution computed tomography (HRCT). The demographic and clinical measurements were recorded on the same day. Plasma samples were centrifuged within 30 minutes at 3,000 rpm for 15 minutes. The plasma was then, removed and stored at -80 0C until the assay. The plasma levels of CLU and α-klotho were analyzed by enzyme-linked immunosorbent assay (ELISA) kits. The present study was conducted in accordance to
the declaration of Helsinki, and the study approval was obtained from Necmettin Erbakan University Meram Faculty of Medicine, Non-interventional Clinical Trials Ethics Committee (Decision No: 2019/2083). Written and informed consent statements were obtained from all participants.

The plasma concentrations of CLU were analyzed by human CLU immunoassay kits. While the minimum detectable concentration (sensitivity) was measured as 0.54 ng/mL, the assay range, intra-assay variation and inter-assay variation were detected as 1-300 ng/mL, <8%, and <10%, respectively. The plasma levels of α-klotho were measured by human α-klotho immunoassay kits. The rates of sensitivity, assay range, intra-assay variation and inter-assay variation were also measured as 0.027 ng/mL, 0.05-20 ng/mL, <8% and <10%, respectively. All procedures were performed under the manufacturers’ instructions for the analyses. The absorbance at 405 nm was recorded by using a microplate reader.

The statistical analyses were carried out with the Statistical Package for the Social Sciences software package for Windows, Version 22.0 (SPSS, Chicago, IL, USA). The differences between the groups were determined with the Mann-Whitney U test. The correlations between the sarcoidosis patients and healthy controls were analyzed by the Spearman’s rank correlation test. The demographic and clinic data of the study groups and the plasma levels of CLU and α-klotho were given as median and range. A p-value less than 0.05 was considered statistically significant.

**RESULTS**

Based on the exclusion criteria, a total of 80 participants were recruited into the study. The plasma CLU levels of sarcoidosis patients and the healthy controls were found as 309.73±40.68 ng/mL and 117.86±102.03 ng/mL, respectively. The plasma CLU levels were observed to be elevated in the healthy group (p=0.005). The plasma levels of α-klotho were measured as 5.34±7.30 ng/mL in the sarcoidosis patients group and 7.21±9.84 ng/mL in the healthy controls. While no significant p values were determined (p=0.338), a minimal decrease was

| Parameters                  | Sarcoidosis Group (n=40) | Healthy Controls (n=40) | p     |
|-----------------------------|--------------------------|-------------------------|-------|
| Age (yrs), mean             | 52.10±12.60              | 37.40±18.20             | 0.058 |
| Sex                         | male, 12 (30%)           | male, 12 (30%)          | 1.00  |
|                             | female, 28 (70%)         | female, 28 (70%)        |       |
| Plasma clusterin, (ng/mL)   | mean: 309.73±40.68       | mean: 117.86±102.03     | 0.005*|
|                             | median: 303.280          | median: 99.810          |       |
|                             | range: (101.15 - 509.50) | range: (99.15 - 275.00) |       |
| Plasma α-klotho, (ng/mL)    | mean: 5.34±7.30          | mean: 7.21±9.84         | 0.338 |
|                             | median: 4.980            | median: 3.305           |       |
|                             | range: (1.77 - 9.16)     | range: (1.15 - 16.51)   |       |
| Ca, (mg/dL)                 | 9.25±0.57                | 8.48±0.34               | 0.436 |
| ESR (mm/h)                  | 22.58±16.7               | 18.21±46.3              | 0.237 |
| Hb, (g/dL)                  | 12.93±1.02               | 14.06±1.50              | 0.012*|
| MCV                         | 82.39±6.97               | 85.7±4.55               | 0.090 |
| CRP, (mg/dL)                | 10.20±12.44              | 9.32±26.14              | 0.129 |
| PLT, Count (106)            | 293200±657.30            | 276666±689.37           | 0.733 |
| MPV                         | 9.60±1.44                | 10.14±1.57              | 0.170 |
| Stage 1 Sarcoidosis         | 10 (25%)                 |                         |       |
| Stage 2 Sarcoidosis         | 26 (65%)                 |                         |       |
| Stage 3 Sarcoidosis         | 3 (7.5%)                 |                         |       |
| Stage 4 Sarcoidosis         | 1 (2.5%)                 |                         |       |
| Extrapulmonary Involvements |                         |                         |       |
| None                        | 29 (72.5%)               |                         |       |
| Skin                        | 4 (10%)                  |                         |       |
| Eye                         | 1 (2.5%)                 |                         |       |
| Nervous system              | 1 (2.5%)                 |                         |       |
| Löfgren                     | 1 (2.5%)                 |                         |       |
| Heart                       | 4 (10%)                  |                         |       |

Ca: Calcium, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, Hb: Hemoglobin, MCV: Mean corpuscular volume, MPV: Mean platelet volume, PLT: Platelet; *A p value of <0.05 was considered as significant.
observed in terms of the plasma α-klotho levels in the patients group, compared to the healthy controls (Table 1). Hemoglobin levels were also measured as 12.93±1.02 g/dL in the sarcoidosis group and 14.06±1.50 g/dL among the controls. The hemoglobin levels of sarcoidosis patients were seen to be lower, compared with the control group (p=0.012). The clinic characteristics and findings of both groups are shown in Table 2. In addition, the predictive power and ROC analysis of CLU and α-klotho are given as Table 3 and

| Parameters                  | Clusterin | p-value | α-klotho | p-value |
|-----------------------------|-----------|---------|----------|---------|
| Calcium (Ca)                | -0.050    | 0.099   | -0.265   | 0.761   |
| ESR                         | 0.036     | 0.169   | 0.222    | 0.824   |
| Hemoglobin (Hb)             | -0.187    | 0.477   | -0.116   | 0.249   |
| MCV                         | 0.220     | 0.715   | 0.060    | 0.173   |
| CRP                         | 0.003     | 0.518   | -0.105   | 0.985   |
| PLT Count (106)             | -0.052    | 0.440   | -0.125   | 0.749   |
| MPV                         | -0.090    | 0.151   | -0.231   | 0.580   |

**Table 2.** Correlation of the laboratory parameters according to plasma clusterin and α-klotho levels in sarcoidosis patients

| Parameters | Cut-off Value | AUC       | Sensitivity | Specificity | PPV  | NPV    |
|------------|---------------|-----------|-------------|-------------|------|--------|
| Clusterin  | 23            | 0.881     | 67.5%       | 72.5%       | 74.50% | 66.89% |
| α-klotho   | 1.05          | 0.387     | 100%        | 95%         | 100%  | 78.71% |

**AUC:** Area under ROC curve, **PPV:** Positive predictive value, **NPV:** Negative predictive value. *Significant as p<0.001

Figure 1 (respectively), and also histogram of CLU in Figure 2.

**DISCUSSION**

Sarcoidosis is a multifactorial disease with unknown aetiology and characterized by non-caseous granulomatous inflammation. The aim of the present study was to determine the plasma CLU and α-klotho levels, and to assess the potential diagnostic role of these biomarkers in the patients

---

**Figure 1.** Receiver operating characteristic (ROC) analyses for clusterin and α-klotho

**Figure 2.** Histogram of clusterin in both groups
with sarcoidosis. Described by the formation of immune granulomas in the organs, sarcoidosis is a condition generally affecting the respiratory system (17). Determining the epidemiology of sarcoidosis is quite difficult due to the unknown causes, lack of precise definition and differences in the presentation for the diagnosis. As a multi-system granulomatous disorder, sarcoidosis is characterized by a T-helper response in which activated macrophages CD4 and lymphocytes accumulate in affected organs (18). In a study performed by Prior et al., it was reported that macrophages and T cells release a wide spectrum of mediators, including chemokines, cytokines and oxygen radicals involved in the pathogenesis of sarcoidosis (19). While the increased oxidative stress was characterised by the abnormality of elevated lipid situation, several oxidative stress markers and lipid situations were significantly linked with sarcoidosis (20).

Recent studies have evaluated the role of CLU in the pulmonary disorders and other related diseases. Several studies have also proposed that the secreted CLU protects cells against various conditions, such as oxidative stress and ionizing radiation. In another study, Carnevali et al. concluded that CLU has a protective role in cigarette smoke-induced oxidative stress in lung fibroblasts (21). Also, a study determined overexpressed CLU levels in non-small cell lung cancer (22). Several studies determined the increased arterial stiffness in sarcoidosis, reflecting an early stage of atherosclerosis. In sarcoidosis, chronic inflammation is one of the fundamental reasons for the atherosclerotic vascular conditions (23). In the study by Aciksari et al., it was concluded that the patients with sarcoidosis had significantly elevated endocan levels and lower brachial arterial flow-mediated dilation than those of the healthy group (24). The same study also proposed that the elevated levels of endocan may be a potential biomarker for the vascular dysfunction in sarcoidosis.

In a recent study, serum adiponectin levels have been emphasized to be higher in sarcoidosis patients, compared to the control group (25). According to the study, a potential predictive role of adiponectin may be associated with some clinical features of sarcoidosis. As similar to the findings of this study, we also determined in our study that plasma CLU levels of sarcoidosis patients were higher than those of the healthy control group (309.73±40.68 and 117.86±102.03 ng/mL, respectively) (p=0.005).

The α-klotho in the circulation exhibits some physiological activities, such as anti-senescence, anti-inflammatory and anti-fibrotic features (26). In an animal study performed on mice, α-klotho deficiency was reported to lead to a shortened lifespan and lung emphysema consistent with aging (27). These results may indicate that α-klotho may have physiological effects on the pulmonary system. Recently, α-klotho has been shown to protect the lungs against the injuries by improving the endogenous antioxidative capacity of pulmonary epithelial cells. While α-klotho is mostly expressed in human airway epithelium, the reduced levels of this protein are observed in the patients with COPD.

The changes occurring in COPD are associated with increased inflammation, oxidative stress and apoptosis in airway epithelial cells (28). In the study by Buendia-Roldan et al., the decreased levels of serum α-klotho were reported to be associated with the reduced lung function in the patients with interstitial lung abnormalities (29). In our study, a decreased plasma α-klotho level was observed in the sarcoidosis group than that of the healthy group, and the difference was not statistically significant (5.34±7.30 and 7.21±9.84 ng/mL, respectively) (p=0.338).

Additionally, hemoglobin levels of sarcoidosis patients were also found to be lower, compared with the healthy control group (p=0.012). From the findings of the present study (Table 2), the clinical and laboratory parameters of both groups are seen not to be statistically different in comparison of the plasma CLU and α-klotho levels.

The present study was performed only in a single province, and the number of study population was limited. For this reason, more comprehensive studies with larger populations are needed to shed light on the entity.

CONCLUSION
The present study demonstrated that the patients with sarcoidosis have higher plasma concentrations of CLU than the healthy subjects. Moreover, the increased concentrations of CLU are positively associated with sarcoidosis and could be a predictive biomarker in the prognosis and diagnosis of sarcoidosis. Further comprehensive and experimental studies will also help determine whether CLU and α-klotho would be of potential therapeutic benefits in the treatment of sarcoidosis.
Conflict of interest: Authors declare that there is no conflict of interest between the authors of the article.

Financial conflict of interest: Authors declare that they did not receive any financial support in this study.

Address correspondence to: Turan Akdag, Necmettin Erbakan University, Meram Vocational School, Konya, Turkey
E-mail: turanakdag570@gmail.com
Phone number: +905056597350

REFERENCES

1. West SG. Current management of sarcoidosis I: Pulmonary, cardiac, and neurologic manifestations. Current opinion in rheumatology 2018;30(3):243-8.
2. Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and management of sarcoidosis. American Family Physician 2016;93(10):840-8.
3. Hunninghake GW, Costabel U, Ando M, et al. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med 1999;160:736-55.
4. Jain R, Yadav D, Puranik N, et al. Sarcoidosis: Causes, diagnosis, clinical features, and treatments. J Clin Med 2020;9:1081.
5. Zissel G. Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 2014;35:307-15.
6. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002;34(5):427-31.
7. Nelson AR, Sagare AP, Zlokovic BV. Role of Clusterin in the brain vascular clearance of amyloid-β. Proc Natl Acad Sci USA 2017;114(33):8681-2.
8. Wang P, Tallicher D, Lakins J, et al. Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur J Biochem 1994;221:917-25.
9. Lin CC, Tsai P, Sun HY, et al. Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production. J Hepatol 2014;61(5):984-93.
10. Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res 2006;40:1324-34.
11. Ma Y, Kong L, Nan K, et al. Apolipoprotein-J prevents angiotensin II-induced apoptosis in neonatal rat ventricular cells. Lipids Health Dis 2015;14:114.
12. Habiel DM, Camelo A, Espindola M, et al. Divergent roles for clusterin in lung injury and repair. Sci Rep 2017;7(1):15444.
13. Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: Implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004;565(1-3):143-7.
14. Torres PU, Prie D, Molina-Blety V, et al. Klotho: An antiaging protein involved in mineral and vitamin D metabolism. Kidney International 2007;71(8):730-7.
15. Rao Z, Landry T, Li P, et al. Administration of alpha klotho reduces liver and adipose lipid accumulation in obese mice. Heliyon 2019;5(4):e01494.
16. Ravikumar P, Ye J, Zhang J, et al. α-Klotho protects against oxidative damage in pulmonary epithelia. Am J Physiol-Lung C 2014;307:7.
17. Jones N, Mochizuki M. Sarcoidosis: Epidemiology and clinical features. Ocul Immunol Inflamm 2010;18(2):72-9.
18. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-73.
19. Prior C, Knight RA, Herold M. Pulmonary sarcoidosis: Patterns of cytokine release in vitro. Eur Respir J 1996;9:47-53.
20. Ivanišević J, Kotur-Stevuljević J, Stefanović A, et al. Dyslipidemia and oxidative stress in sarcoidosis patients. Clin Biochem 2012;45(9):677-82.
21. Carnevali S, Luppi F, D’Arca D, et al. Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke. Am J Respir Crit Care Med 2006;174(4):393-9.
22. July LV, Beraldi E, So A, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004;3:223-32.
23. Ardic I, Yarlogilues M, Dogdu O, et al. Assessment of aortic elastic properties in patients with sarcoidosis. Blood Press 2012;21(5):286-92.
24. Aciksari G, Kavas M, Atici A, et al. Endocan levels and endothelial dysfunction in patients with sarcoidosis. Angiology 2018;69(10):878-83.
25. Kobak S, Semiz H, Akyildiz M, et al. Serum adipokine levels in patients with sarcoidosis. Clin Rheumatol 2020;39:2121-5.
26. Guan X, Guan X, Nie L, et al. Klotho suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. J Pathol 2014;234(4):560-72.
27. Kuro-o M. Klotho and aging. Biochim Biophys Acta 2009;1790(10):1049-58.
28. Gao W, Yuan C, Zhang J, et al. Klotho expression is reduced in COPD airway epithelial cells: Effects on inflammation and oxidant injury. Clin Sci 2015;129(12):1011-23.
29. Buendia-Roldan I, Machuca N, Mejia M, et al. Lower levels of α-Klotho in serum are associated with decreased lung function in individuals with interstitial lung abnormalities. Sci Rep 2019;9:10801.